Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
Sharlene Dong, MD (she/her/hers)
Chief Resident
UT Southwestern Medical Center, United States